Marker Therapeutics Inc (MRKR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.18-4.84%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · MRKR
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | — | 3.5 | 6.6 | 3.3 | 3.5 | 0.0 | 0.5 | 0.2 | 0.2 | — | — | — | — | — | — | — |
| Total Revenues | — | — | — | — | — | 0.0 | 0.5 | 0.2 | 0.2 | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | 8.8 | 11.8 | 13.5 | 10.4 | 12.0 | 27.8 | 18.9 | 12.8 | 8.0 | 5.3 | 3.8 | 1.7 | 0.2 | 0.7 | 1.1 | 0.2 |
| Operating Income | (9.5) | (12.9) | (11.1) | (14.6) | (19.8) | (39.5) | (28.9) | (22.5) | (148.2) | (11.5) | (8.5) | (6.2) | (3.4) | — | — | (3.3) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest & Investment Income | 0.5 | 0.6 | 0.4 | 0.5 | 0.2 | 0.0 | 0.1 | 1.1 | 0.3 | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | — | (12.2) | (10.7) | (14.0) | (19.8) | — | — | — | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | (0.0) | 0.0 | 0.0 | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — | — |
| Earnings from Continuing Operations | — | — | (10.7) | (14.0) | (19.8) | — | — | — | — | — | — | — | — | — | — | — |
| Net Income | ||||||||||||||||
| Net Income | (8.7) | (12.2) | (10.7) | (8.2) | (29.9) | (41.9) | (28.7) | (21.4) | (148.0) | (11.0) | (2.5) | (34.1) | (30.9) | — | (5.9) | (2.0) |
| Per Share | ||||||||||||||||
| Basic EPS | (0.45) | (0.79) | (1.19) | (0.94) | (3.58) | (5.47) | (0.61) | — | — | (1.16) | (0.36) | — | — | — | — | — |
| Diluted EPS | (0.45) | (0.79) | (1.19) | (0.94) | (3.58) | (5.47) | (0.61) | — | — | (1.16) | (0.72) | — | — | — | — | — |
| Basic Weighted Avg Shares | 19.3 | 15.3 | 9.0 | 8.8 | 8.4 | 7.7 | 47.0 | 45.6 | 19.1 | 9.5 | 6.9 | — | — | — | — | — |
| Diluted Weighted Avg Shares | 19.3 | 15.3 | 9.0 | 8.8 | 8.4 | 7.7 | 47.0 | — | — | 9.5 | 7.4 | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | — | — | — | (17.0) | (37.3) | (28.4) | (22.4) | — | — | — | — | — | — | — | — |
| EBIT | (9.5) | (12.9) | (11.1) | (14.6) | (19.8) | (39.5) | (28.9) | (22.5) | (148.2) | (11.5) | (8.5) | (6.2) | (3.4) | — | — | (3.3) |
| Effective Tax Rate | — | — | — | -0.0% | — | — | — | — | — | — | — | — | — | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.